Mirati Therapeutics names David Meek as CEO

20 September 2021

US clinical-stage targeted oncology company Mirati Therapeutics (Nasdaq: MRTX) today announced the appointment of industry veteran David Meek as chief executive (CEO), effective immediately.

Mr Meek will also join the company's board of directors. Dr Charles Baum, will continue to lead the research and development (R&D) organization as president, founder and head of R&D. Dr Baum will remain on the company's board.

Mr Meek has over 30 years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology, including as CEO of French drugmaker Ipsen (Euronext: IPN), a leading global biopharmaceutical company, where is resignation in December 2019 caused investor consternation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK